Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.

Neal D Shore Arnulf StenzlChristopher PieczonkaZachary KlaassenWilliam J AronsonLawrence KarshCharles J RyanJorge OrtizShankar SrinivasanAteesha F MohamedFrank Verholen

Published in: BJU international (2022)

Darolutamide demonstrated a positive impact on local disease recurrence and symptom control in patients with nmCRPC, delayed time to deterioration in QoL related to urinary and bowel symptoms, and a favourable safety profile showing similar incidence of urinary- and bowel-related AEs compared with placebo.

Keyphrases

phase iii
clinical trial
sleep quality
risk factors
randomized controlled trial
phase ii
physical activity
depressive symptoms
double blind
open label